Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) and Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
Risk & Volatility
Aclaris Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of -0.42, meaning that its stock price is 142% less volatile than the S&P 500.
Earnings & Valuation
This table compares Aclaris Therapeutics and Jaguar Animal Health”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclaris Therapeutics | $18.72 million | 15.34 | -$132.07 million | ($1.38) | -1.92 |
| Jaguar Animal Health | $11.79 million | 0.33 | -$38.49 million | ($33.24) | -0.03 |
Jaguar Animal Health has lower revenue, but higher earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Aclaris Therapeutics and Jaguar Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aclaris Therapeutics | -900.01% | -39.73% | -27.98% |
| Jaguar Animal Health | -341.90% | -1,194.94% | -80.16% |
Insider & Institutional Ownership
98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are owned by institutional investors. 5.6% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 7.5% of Jaguar Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Aclaris Therapeutics and Jaguar Animal Health, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclaris Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
| Jaguar Animal Health | 1 | 0 | 1 | 0 | 2.00 |
Aclaris Therapeutics currently has a consensus price target of $9.75, indicating a potential upside of 267.92%. Jaguar Animal Health has a consensus price target of $60.00, indicating a potential upside of 5,725.24%. Given Jaguar Animal Health’s higher possible upside, analysts clearly believe Jaguar Animal Health is more favorable than Aclaris Therapeutics.
Summary
Aclaris Therapeutics beats Jaguar Animal Health on 9 of the 14 factors compared between the two stocks.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
